• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Genotype 3-hepatitis C virus' last line of defense

    2021-04-01 09:13:16DorotaZarebskaMichaluk
    World Journal of Gastroenterology 2021年11期

    Dorota Zarebska-Michaluk

    Abstract Chronic infection with hepatitis C virus (HCV) is one of the leading causes of liver disease globally, affecting approximately 71 million people. The majority of them are infected with genotype (GT) 1 but infections with GT3 are second in frequency. For many years, GT3 was considered to be less pathogenic compared to other GTs in the HCV family due to its favorable response to interferon (IFN)-based regimen. However, the growing evidence of a higher rate of steatosis, more rapid progression of liver fibrosis, and lower efficacy of antiviral treatment compared to infection with other HCV GTs has changed this conviction. This review presents the specifics of the course of GT3 infection and the development of therapeutic options for GT3-infected patients in the era of direct-acting antivirals (DAA). The way from a standard of care therapy with pegylated IFNalpha (pegIFNα) and ribavirin (RBV) through a triple combination of pegIFNα + RBV and DAA to the highly potent IFN-free pangenotypic DAA regimens is discussed along with some treatment options which appeared to be dead ends. Although the implementation of highly effective pangenotypic regimens is the most recent stage of revolution in the treatment of GT3 infection, there is still room for improvement, especially in patients with liver cirrhosis and those who fail to respond to DAA therapies, particularly those containing inhibitors of HCV nonstructural protein 5A.

    Key Words: Hepatitis C virus; Genotype 3; Antiviral treatment; Interferon; Direct-acting antivirals; Pangenotypic

    INTRODUCTION

    Chronic infection with hepatitis C virus (HCV) is assumed to be one of the leading causes of liver disease globally, affecting approximately 71 million people[1]. Due to the high genetic diversity of the viral nucleic acid sequence, six major genotypes (GT), differing from each other by 30% at the nucleotide level, comprising multiple subtypes of HCV, have been identified[2]. The majority of patients worldwide are infected with GT1, but infections of GT3 are also common in some regions. GT3 is defined by a higher rate of steatosis, increased risk of liver cirrhosis, and different response to antiviral drugs compared to other GTs. In the era of treatment with pegylated interferon alpha (IFNα) and ribavirin (RBV), patients infected with GT3 were considered "easy to treat" due to an efficacy rate of 70%, compared to less than 50% in GT1 and GT4 infected patients. The introduction of direct-acting antivirals (DAA) has changed the management of HCV infection, allowing a substantial increase in the treatment efficacy, however, the improvement for GT3 infection was not as pronounced as for other GTs, particularly in treatment-experienced patients and those with liver cirrhosis.

    THE GLOBAL SPREAD OF GT3

    GT3 infections are widely distributed worldwide and are estimated to be the second in frequency accounting for approximately 25%-30% of all HCV cases globally[2]. The distribution of GT3 varies between different countries and continents. The highest global prevalence (exceeding 70%) is found in South Asian countries, while a rate of approximately 20% is reported in Central and Southeast Asia, a few percent in East Asia, and only 0.4% in the Asia-Pacific region. A relatively high frequency of 36% is documented in Australia[3]. GT3 infection accounts for 14.2% of HCV cases in South America, 2.1% in Central America, and 15.7% in North America, ranging from 8.9% in the United States to 22.3% in Canada[3]. In Europe, the distribution of GT3 infections is also heterogeneous with the highest frequency exceeding 40% in Scandinavia and England, over 30% in Ireland, Greece Russia, and Slovenia, and more than 20% of infections in Germany, Switzerland, Montenegro, Belgium, Bosnia, and France[4-6]. The rate of a dozen percent is reported from Spain, Poland, Portugal, Bulgaria, and Croatia, whereas the lowest prevalence, below 10%, are documented in Italy, Albania, Hungary, and Romania[7-10]. The lowest proportional frequency of GT3 infections is found in Africa at an average of 5.3%, with the highest frequency at 7.4% in East Africa through 6.3% in North Africa to 0.8% in the central part of the continent[3].

    GOOD OR BAD IN THE HCV FAMILY

    For many years, GT3 was considered to be less pathogenic compared to other GTs in the HCV family due to its favorable response to an IFN-based regimen. However, the growing evidence of a higher rate of steatosis and more rapid progression of liver fibrosis compared to infection with other HCV GTs has changed this conviction.

    Liver steatosis is a frequent histological finding in patients with chronic hepatitis C (CHC). Although this feature is common among all HCV infected individuals, with an average rate of 50%, the highest prevalence exceeding 70% is observed in patients infected with GT3[11-14]. In in-vitro studies, GT3 is also demonstrated to be much more likely to induce liver steatosis than other HCV GTs[15]. The pathogenesis of hepatic steatosis is complex and related to host and viral factors, as well as to alcohol consumption. Metabolic steatosis, which is associated with host risk factors including high body mass index, obesity, dyslipidemia, metabolic syndrome, insulin resistance and type 2 diabetes, is commonly found in patients infected with non-GT3 HCV, whereas in the GT3-infected individuals, virus-related hepatic steatosis is described as predominantly being induced by the direct cytopathic effect of the HCV[16-20]. Although the exact mechanism remains unknown, several pathways are linked to the pathogenesis of GT3-induced steatosis. A central role is played by the inhibition of microsomal triglyceride transfer protein function by HCV core protein, resulting in overall decreased hepatocyte lipid export with intracellular triglycerides accumulation. This effect is documented to be amplified with HCV-3 core proteins[21]. Another mechanism through which the virus modulates the host lipid metabolic pathways is inhibition of the peroxisome proliferator associated receptor-α (PPAR-α), a transcription factor inducing hepatic fatty acid oxidation and ketogenesis. A decrease in PPAR-α level leads to hepatic lipid collection. In vitro studies document inhibition of PPAR-α observed in the GT3 infections as being more efficient than in infections with GT1 HCV[22]. Viral-induced hepatic steatosis results not only from the reduction of the lipid excretion with subsequent intracellular lipid accumulation but also from the promotion of the neolipogenesis with fatty acid synthesis. This activity is proposed to be a consequence of an increase in function of sterol regulatory element-binding protein-1c activated by the HCV-3 core protein, however, the exact mode of activation is unknown[23]. The hypothesis of a pathogenic link between GT3 infection and steatosis is supported by a significant correlation of the steatosis score and intrahepatic titer of HCV RNA only in patients infected with GT3[16]. The improvement in liver steatosis in GT3-infected patients after successful antiviral therapy, which is not observed in patients infected with GT1, seems to indirectly confirm this association[24,25]. GT3 HCV was also identified as an independent predictor for the accelerated progression of liver fibrosis in addition to established risk factors including the age of infection, male gender, coinfection with hepatitis B virus and human immunodeficiency virus, insulin resistance, iron overload, alcohol and drugs intake[26]. Precise analysis of the influence of HCV GT on the more advanced liver disease is difficult due to the coexistence of the aforementioned predictors and the previously discussed higher prevalence of liver steatosis in GT3 infection, which contributes to more rapid progression of hepatic fibrosis[12,27,28]. However, the pooled analysis con?rmed a signi?cantly more severe liver disease in single-biopsy studies and a trend towards the faster progression of fibrosis in GT3 patients compared with the other GTs[29]. The strong association between GT3 infection and end-stage liver disease was documented in HCV-infected drug abusers in France and confirmed by a populationbased study in a cohort of native Alaskans with CHC[30,31].

    An increased risk not only of liver cirrhosis but also of hepatocellular carcinoma (HCC) among GT3 infected individuals compared to those infected with other GTs was reported in a large cohort (> 110000) of American patients from the Veterans Affairs Registry[32,33]. Consistent results of significantly higher incidence of HCC in GT3 patients were also obtained in French and Korean populations[34,35]. Nevertheless, the effect of HCV GT3 infection on the higher prevalence of liver cancer remains controversial because of the data demonstrated for GT1b as a major risk factor for HCC development[36,37].

    IFN AND RBV COUPLE

    The standard of care therapy of pegylated (peg) IFNα and RBV established in 2000 has resulted in a sustained virologic response (SVR) of approximately 70% in GT3-infected patients[38-42]. Such a high effectiveness compared to the SVR below 50% achieved by patients with GT1 and GT4 infection was the basis for the GT3 being deemed "easy to treat" and has led to attempts to shorten the treatment course to 16, 14, and even 12 wk. However, the reduction in the SVR rate was reported in patients who did not achieve the so-called rapid virologic response (RVR) defined as undetectability of HCV RNA after 4 wk of therapy[38,39,42-44]. The meta-analysis of twelve clinical trials performed by Andriulli et al[45]documented a wide variance in response to pegIFNα and RBV in GT3-infected patients depending on the baseline viral load. Individuals with a high baseline level of HCV RNA demonstrated a significantly lower SVR rate of 58% compared to 75% in those with a low baseline viral load. The strongest predictive factor for treatment response was RVR and this finding provided the basis for the conclusion that patients without RVR may need a longer therapy duration. The negative impact of cirrhosis on treatment response among subjects infected with GT3, leading to poor antiviral effectiveness was documented by Powis et al[46], suggesting that such patients also require an alternative management strategy. However, the extension of the treatment course did not result in higher effectiveness, nor was there an improvement in the SVR rate on increasing the dose of RBV[47-49].

    THE COUPLE WITH A LITTLE HELP OF DAA

    The registration of the first DAAs in 2011, which were inhibitors of the HCV serine protease (nonstructural protein 3/4A, NS3/4A), started a revolution in the treatment of CHC. The combination of telaprevir or boceprevir with pegIFNα and RBV significantly increased the SVR rate, but only in patients infected with GT1[50,51]. Those infected with other GTs, including GT3, were still treated with pegIFNα and RBV because no significant improvement was demonstrated after the addition of telaprevir or boceprevir[52,53]. Therefore, at the beginning of the DAA era GT3 emerged as a "difficult-to-treat" GT. New hopes for higher effectiveness were raised with the introduction of the next-generation DAAs for possible combination with pegIFNα and RBV. Unfortunately, clinical trials demonstrated that simeprevir, a second-wave protease inhibitor with documented in-vitro pangenotypic activity has limited efficacy in GT3-infected patients, and the effectiveness of daclatasvir (DCV), acting through inhibition of the HCV nonstructural protein 5A (NS5A), has proven to be also disappointing, with SVR rates of 45% and 74% in GT3 patients with and without liver cirrhosis, respectively[54,55]. However, the expectations of a higher response rate among GT3-infected patients have been met by sofosbuvir (SOF), a new DAA class representative, HCV polymerase (NS5B) inhibitor. The addition of SOF to pegIFNα and RBV (SPR) leads to better outcomes when compared to standard of care therapy, regardless of liver fibrosis and history of previous antiviral therapy. Phase 2 clinical trials documented a response of 83% among treatment-experienced patients with liver cirrhosis participating in the LONESTAR-2 study, while non-cirrhotic, treatment-na?ve individuals treated in the QUANTUM study responded in 92% of cases[56,57].

    Patients included in the BOSON phase 3 clinical trial achieved an SVR of 93%, specifically 88% among individuals with liver cirrhosis and 95% in those without; the lowest efficacy of 86% was demonstrated for patients with liver cirrhosis who failed to respond to previous antiviral therapy[58]. An open-label clinical study evaluating the outcome of SOF-containing treatments reported 100% efficacy among GT3-infected treatment na?ve patients without cirrhosis treated with triple therapy[59].

    Those results from clinical trials were supported by real-world experience (RWE) data that documented an SVR rate higher than that following dual therapy. The best response of 93% was reported for non-cirrhotics among Americans treated in the Veterans Affairs health care system[60]. Scandinavian patients responded in 96% of cases, an efficacy of 98% was obtained in the Polish EpiTer-2 study and an SVR reached 99% in a German cohort[6,61,62]. The effectiveness of the SPR regimen in cirrhotic individuals in these RWE studies was also promising, reaching 92%, 81%, 91%, and 88%, respectively[6,60-62].

    RWE data revealed a failure of previous therapy, with a history of treatment with IFN and RBV shown to be a negative prognostic factor of the response to SPR treatment. This triple regimen was still recommended by the guidelines of the European Association for the Study of the Liver in 2015 for GT3-infected non-cirrhotic patients and those with compensated liver cirrhosis, regardless of treatment history[63]. Irrespective of the high effectiveness of SPR, accompanied by reasonable tolerability due to the short treatment period, any IFN-based therapy was refused by patients[61]. Therefore, further research on the treatment of GT3 infections has focused on highly efficient IFN-free therapeutic options.

    DAA HOME ALONE

    The first available IFN-free regimen, SOF and RBV, used in GT3-infected patients for 12 wk or 16 wk, did not result in increased efficacy when compared to standard of care therapy, which demonstrated significantly lower response rates in patients with liver cirrhosis, especially in those who had previously failed IFN and RBV therapy (Table 1)[40,58,64].

    The extension of treatment duration to 24 wk enabled effectiveness of up to 95%,however, the difference in response rates between patients without and with liver cirrhosis was significant[58,65]. The results of phase 3 clinical trials confirmed by RWE data became a basis for treatment guidelines, according to which IFN-ineligible GT3-infected patients should receive SOF/RBV for 24 wk. However, this regimen was recognized as suboptimal, due to unsatisfactory effectiveness for those with liver cirrhosis who had previously failed IFN and RBV therapy[66-68].

    Table 1 Efficacy of interferon-free regimens in genotype 3 patients in clinical trials

    1NS5A-inhibitor-experienced.2No detailed information on the response rate in patients with and without liver cirrhosis.3Recommended by American Association for the Study of Liver Diseases/Infectious Diseases Society of America as an alternative option for pegylated interferon + ribavirin-experienced patients with compensated liver cirrhosis. SVR: Sustained virologic response; GT: Genotype; SOF: Sofosbuvir; RVB: Ribavirin; DCV: Daclatasvir; VEL: Velpatasvir; VOX: Voxilaprevir; GLE: Glecaprevir; PIB: Pibrentasvir; LDV: Ledipasvir; ALV: Alisporivir; OBV: Ombitasvir; PTV/r: Paritaprevir boosted by ritonavir; GZR: Grazoprevir; EBR: Elbasvir; UPR: Uprifosbuvir; RBV: Ribavirin; RZR: Ruzasvir.

    Searching for the optimal antiviral regimen, the combinations of SOF and another DAA with a different mechanism of action were studied. Promising results were obtained with a SOF and DCV combination administered for 12 wk and 24 wk, with or without RBV[69-71]. Although the difference in response rates with SOF + DCV ± RBV between non-cirrhotic and cirrhotic patients was still noticeable, this regimen was recommended for the treatment for GT3-infected patients regardless of liver fibrosis and history of previous therapy and has been widely used in RWE settings[66,72-74]. High efficacy and good tolerability demonstrated in both clinical trials and real-world cohorts have made this regimen a reasonable choice for therapy for GT3 infection as long as highly potent pangenotypic options became broadly available[75-77].

    BETTER IS THE ENEMY OF GOOD ENOUGH

    The final stage of the revolution in antiviral treatment which improved the outcome and simplified the management of GT3-infected patients was the implementation of potent pangenotypic regimens (Table 1).

    According to the most recent guidelines, two basic options of DAAs are currently approved for the treatment of GT3 infection; a fixed-dose combination of SOF and velpatasvir (VEL), and dual treatment with glecaprevir (GLE), an NS3/4A protease inhibitor, and pibrentasvir (PIB), an NS5A inhibitor (Table 2)[78,79]. A single-tablet regimen containing SOF and VEL was registered based on the results of the ASTRAL-3 study, which confirmed effectiveness exceeding 93% in non-cirrhotic and 89% in cirrhotic patients[80]. The 12-wk regimen is recommended for non-cirrhotics and patients with compensated cirrhosis, regardless of the previous treatment history. The addition of RBV may be considered in compensated individuals.

    It is noteworthy that SOF/VEL combined with RBV is the only option recommended for patients with decompensated liver cirrhosis[81,82]. Data on the high efficacy and favorable safety profile of SOF/VEL achieved in clinical trials were supported by RWE studies reporting comparable SVR rates. Prior treatment-experience, as well as advanced liver fibrosis, were significant predictors of reduced effectiveness[83-87]. As resistance-associated substitutions at the NS5A position can be responsible for a reduction in the efficacy of the NS5A inhibitors, the resistance-associated substitutions testing at baseline should be considered for treatment-experienced patients and cirrhotic individuals, irrespective of treatment history, for whom SOF/VEL is being considered. The identification of the Y93H substitution indicates the need for RBV addition or an alternative regimen administration[78,79].

    The second potent pangenotypic option is a combination of GLE and PIB, which was approved for the treatment of patients without or with liver cirrhosis irrespective of previous therapy. As protease inhibitors containing regimens carry a risk of decompensation during antiviral treatment, GLE/PIB is not recommended for decompensated cirrhotic patients[88]. This regimen provides the opportunity for shortening therapy to 8 wk in the majority of patients[89]. Based on findings from the ENDURANCE-3, SURVEYOR-II, and EXPEDITION-8 clinical trials, an 8-wk regimen has been registered for all previously untreated patients, including those with compensated liver cirrhosis, whereas treatment-experienced GT3-infected individuals should be treated for 16 wk regardless of liver fibrosis[90-94]. RWE studies reported effectiveness for an 8-wk GLE/PIB regimen, which exceeded 96% in treatment-na?ve patients without liver cirrhosis[95-99]. Since the shortening of therapy in previously untreated cirrhotic patients infected with GT3 has been approved very recently, the available RWE data are very limited and only include a small number of patients[100,101]. Therefore, further studies are needed to determine the treatment outcome in this subpopulation. Although the implementation of SOF/VEL and GLE/PIB regimens has resulted in a high efficacy rate among GT3-infected individuals, there is still room for improvement, especially in those who did not achieve SVR, particularly following NS5A containing regimens. For such patients, a 12-wk salvage therapy with a singletablet combination of SOF/VEL and next-generation NS3/4A protease inhibitor voxilaprevir (VOX) is recommended[102]. Safety and efficacy of SOF/VEL/VOX in GT3-infected patients without and with liver cirrhosis, both treatment-na?ve and treatmentexperienced were demonstrated in the POLARIS studies (Table 1)[102,103].

    The other option to address failed DAA treatment in GT3-infected patients is a combination of GLE/PIB plus SOF and RBV, as investigated in the MAGELLAN-3 study. This demonstrated a 100% SVR rate, however, the small number of patients enrolled may have limited the broad applicability of these findings[104].

    SOMETHING WENT WRONG

    On the way to developing highly effective pangenotypic regimens against GT3, there were multiple paths that appeared to be dead ends. Some of them were not investigated despite showing encouraging initial results, due to disappointing treatment outcomes in selected subpopulations of GT3 patients. One good example is an open-label study of 12-wk treatment with an NS5A inhibitor—ledipasvir and SOF, plus RBV, which demonstrated a 100% SVR rate among treatment-na?ve GT3 infected individuals. Unfortunately, due to limited efficacy in treatment-experienced patients, especially those with liver cirrhosis, as well as low antiviral potency without RBV against GT3, that direction of search has proved a blind alley[105]. Alisporivir, a cyclophilin inhibitor, applied alone or with RBV in treatment-na?ve non-cirrhotic patients has resulted in SVR rates of 76% and 93%, respectively, however, research involving other subgroups of patients was suspended due to a safety issue[106]. Efficacy was observed to be below expectations with the combination of the NS3/4A inhibitor grazoprevir (GZR) and the NS5A inhibitor elbasvir (EBR) with RBV, as well as with a regimen consisting of the NS5A inhibitor ruzasvir and the NS5B inhibitor uprifosbuvir[107,108]. The unsatisfactory outcome of the treatment with NS35A inhibitor ombitasvir, and NS3/4A inhibitor paritaprevir boosted by ritonavir with or without RBV, was subsequently improved by the addition of SOF, but ultimately these regimens were not further evaluated, because there were new potent pangenotypic options on the horizon[109,110]. For this same reason, investigations into a regimen of GZR/EBR combined with uprifosbuvir or SOF were discontinued, despite the high effectiveness demonstrated in phase 2 clinical trials. However, GZR/EBR + SOF is currently recommended by AASLD/IDSA as an alternative option for the specific subpopulation of pegIFNα+RBV-experienced patients with compensated liver cirrhosis[79,111-113].

    Table 2 European Association for the Study of the Liver and American Association for the Study of Liver Diseases/Infectious Diseases Society of America current recommendations on the treatment of genotype 3-infected patients

    CONCLUSION

    Despite the high efficacy and safety of pangenotypic therapies, that may sooner or later cure all or at least almost all identified HCV infections, including GT3, there will still be many infections that go unrecognized and are therefore impossible to cure with even the best drug. The major problem that remains to be solved worldwide is screening people who are unaware of the risk of liver disease progression from a virus in their body. It is a shame for national governments that, despite having access to the perfect tool to eliminate a dangerous virus and rule out one of the most difficult-totreat cancers, are not doing enough.

    97碰自拍视频| 最近视频中文字幕2019在线8| 丰满人妻一区二区三区视频av| 三级男女做爰猛烈吃奶摸视频| 国产精品一区二区免费欧美| 国产黄色视频一区二区在线观看 | 国产伦精品一区二区三区四那| 夜夜爽天天搞| 午夜福利18| 亚洲中文字幕日韩| 成人永久免费在线观看视频| 国产久久久一区二区三区| 亚洲人与动物交配视频| 欧美最新免费一区二区三区| 欧美性感艳星| 日本 av在线| 午夜福利在线观看免费完整高清在 | 欧美区成人在线视频| 97超级碰碰碰精品色视频在线观看| 亚洲三级黄色毛片| 亚洲七黄色美女视频| 亚洲av二区三区四区| 日本a在线网址| 少妇熟女aⅴ在线视频| 欧美一区二区国产精品久久精品| 亚洲人成网站高清观看| 在线免费观看的www视频| 一本精品99久久精品77| 久久久久久伊人网av| 尤物成人国产欧美一区二区三区| 日本 av在线| 国产视频一区二区在线看| 3wmmmm亚洲av在线观看| 国产白丝娇喘喷水9色精品| 国产aⅴ精品一区二区三区波| 美女cb高潮喷水在线观看| 国产欧美日韩精品亚洲av| 男女啪啪激烈高潮av片| av.在线天堂| 国产精品亚洲美女久久久| 国产色爽女视频免费观看| 蜜桃久久精品国产亚洲av| 国产av一区在线观看免费| 国产aⅴ精品一区二区三区波| 国产av一区在线观看免费| 人人妻人人看人人澡| 丝袜喷水一区| 可以在线观看毛片的网站| 成人一区二区视频在线观看| 欧美高清成人免费视频www| 欧美人与善性xxx| 日本成人三级电影网站| 国产乱人视频| 亚洲美女黄片视频| 香蕉av资源在线| 亚洲内射少妇av| 综合色av麻豆| 欧美xxxx黑人xx丫x性爽| 午夜福利在线观看吧| 一本久久中文字幕| 国产黄色视频一区二区在线观看 | 91在线精品国自产拍蜜月| 欧美成人a在线观看| 在线看三级毛片| 成年av动漫网址| 一级毛片aaaaaa免费看小| 搞女人的毛片| 中文亚洲av片在线观看爽| 亚洲电影在线观看av| 国产精品永久免费网站| 久久精品国产清高在天天线| 久久精品久久久久久噜噜老黄 | 九九久久精品国产亚洲av麻豆| 色综合色国产| 午夜精品国产一区二区电影 | 尤物成人国产欧美一区二区三区| 久久久久国内视频| 国内精品一区二区在线观看| av中文乱码字幕在线| 亚洲av成人av| 搞女人的毛片| 国产亚洲精品久久久com| 我要看日韩黄色一级片| 在线观看一区二区三区| 国产三级在线视频| 成人综合一区亚洲| 午夜爱爱视频在线播放| 国产高清有码在线观看视频| 久久久成人免费电影| 伦理电影大哥的女人| 国产日本99.免费观看| 婷婷六月久久综合丁香| 又黄又爽又免费观看的视频| 午夜激情欧美在线| 日韩三级伦理在线观看| 97碰自拍视频| 十八禁国产超污无遮挡网站| 亚洲成人久久性| 亚洲最大成人中文| 久久中文看片网| 欧美日本视频| 精品日产1卡2卡| 在线观看午夜福利视频| 欧美日韩精品成人综合77777| 欧美高清成人免费视频www| 欧美激情在线99| 日韩三级伦理在线观看| 精品人妻偷拍中文字幕| 国产精品国产高清国产av| 免费看光身美女| 麻豆一二三区av精品| 真实男女啪啪啪动态图| 免费观看的影片在线观看| 高清毛片免费观看视频网站| 老司机午夜福利在线观看视频| 99热精品在线国产| 国产aⅴ精品一区二区三区波| 简卡轻食公司| 岛国在线免费视频观看| av天堂中文字幕网| 日本一二三区视频观看| 成年女人永久免费观看视频| 自拍偷自拍亚洲精品老妇| 国内精品一区二区在线观看| 国产69精品久久久久777片| 国产亚洲av嫩草精品影院| 精品熟女少妇av免费看| 免费一级毛片在线播放高清视频| 日韩亚洲欧美综合| 欧美一区二区亚洲| 国产爱豆传媒在线观看| 亚洲最大成人中文| 人妻久久中文字幕网| 亚洲国产精品成人综合色| 久久精品国产亚洲av香蕉五月| 夜夜看夜夜爽夜夜摸| 国产精品不卡视频一区二区| 国产在线精品亚洲第一网站| 欧美成人免费av一区二区三区| 麻豆av噜噜一区二区三区| 亚洲欧美中文字幕日韩二区| 狂野欧美白嫩少妇大欣赏| 欧美国产日韩亚洲一区| 国产成人影院久久av| 亚洲内射少妇av| 国产爱豆传媒在线观看| 欧美激情国产日韩精品一区| 三级毛片av免费| 少妇的逼好多水| 国产亚洲91精品色在线| 欧美精品国产亚洲| 99久久精品热视频| 最好的美女福利视频网| 99视频精品全部免费 在线| 99视频精品全部免费 在线| 久久精品国产自在天天线| 国内揄拍国产精品人妻在线| 又粗又爽又猛毛片免费看| 天堂av国产一区二区熟女人妻| 中文在线观看免费www的网站| 国产v大片淫在线免费观看| 色综合站精品国产| 黄色一级大片看看| 亚洲,欧美,日韩| 日韩欧美在线乱码| 国产又黄又爽又无遮挡在线| 久久草成人影院| 欧美中文日本在线观看视频| 国产亚洲av嫩草精品影院| 亚洲美女黄片视频| 成年版毛片免费区| 天堂av国产一区二区熟女人妻| 欧美中文日本在线观看视频| 男人的好看免费观看在线视频| 欧美性猛交黑人性爽| 国产黄a三级三级三级人| 国产精品,欧美在线| 高清日韩中文字幕在线| 国内揄拍国产精品人妻在线| 日韩欧美 国产精品| 99久久精品一区二区三区| 麻豆国产97在线/欧美| 国产 一区精品| 国产一级毛片七仙女欲春2| 国产午夜精品论理片| 亚洲国产精品合色在线| 成人精品一区二区免费| 99在线视频只有这里精品首页| 国产亚洲av嫩草精品影院| 国产精华一区二区三区| 久久国内精品自在自线图片| 最近在线观看免费完整版| 午夜福利高清视频| 伦精品一区二区三区| 国产精品电影一区二区三区| 一本精品99久久精品77| 级片在线观看| 国产成人影院久久av| 日本五十路高清| 亚洲国产高清在线一区二区三| 午夜免费男女啪啪视频观看 | 久久精品91蜜桃| 欧美日韩一区二区视频在线观看视频在线 | 麻豆国产97在线/欧美| 搡老岳熟女国产| 日本黄大片高清| 亚洲欧美日韩东京热| 国产av麻豆久久久久久久| 桃色一区二区三区在线观看| 综合色丁香网| 国产黄色小视频在线观看| 国产黄色小视频在线观看| 日本爱情动作片www.在线观看 | 精品一区二区三区视频在线| 亚洲真实伦在线观看| 你懂的网址亚洲精品在线观看 | 一级a爱片免费观看的视频| 三级男女做爰猛烈吃奶摸视频| 国产综合懂色| 蜜桃亚洲精品一区二区三区| 午夜精品在线福利| 哪里可以看免费的av片| 亚洲精品在线观看二区| 国产高潮美女av| 免费无遮挡裸体视频| 国产精品亚洲美女久久久| 中文字幕久久专区| 乱系列少妇在线播放| 国产男靠女视频免费网站| 全区人妻精品视频| av.在线天堂| 免费无遮挡裸体视频| 尾随美女入室| 人人妻人人看人人澡| 午夜日韩欧美国产| 啦啦啦韩国在线观看视频| 精品久久久久久成人av| 久久久色成人| 狂野欧美白嫩少妇大欣赏| 欧美3d第一页| 成人无遮挡网站| 中国美女看黄片| 亚洲不卡免费看| 高清午夜精品一区二区三区 | 黄色配什么色好看| 免费观看在线日韩| 人人妻人人澡欧美一区二区| 黄片wwwwww| 人人妻,人人澡人人爽秒播| 国产精品无大码| 久久婷婷人人爽人人干人人爱| 在线免费观看的www视频| 亚洲国产精品sss在线观看| 久久欧美精品欧美久久欧美| 99国产极品粉嫩在线观看| 国产精品无大码| 国产男靠女视频免费网站| 精品一区二区三区人妻视频| 嫩草影视91久久| 日产精品乱码卡一卡2卡三| 日韩欧美精品v在线| 九九久久精品国产亚洲av麻豆| 天堂动漫精品| 日韩av在线大香蕉| 精品日产1卡2卡| 搡老熟女国产l中国老女人| 高清午夜精品一区二区三区 | 久久久久久久亚洲中文字幕| 亚洲综合色惰| 麻豆av噜噜一区二区三区| 亚洲人与动物交配视频| 美女高潮的动态| 国产精品伦人一区二区| 成人无遮挡网站| а√天堂www在线а√下载| 欧美成人一区二区免费高清观看| 国产麻豆成人av免费视频| 亚洲欧美日韩高清在线视频| 永久网站在线| 国产精品日韩av在线免费观看| 久久九九热精品免费| 国产精品人妻久久久久久| 国产高清不卡午夜福利| 久久精品久久久久久噜噜老黄 | 校园春色视频在线观看| 成人欧美大片| 日本黄色视频三级网站网址| 色在线成人网| av.在线天堂| 菩萨蛮人人尽说江南好唐韦庄 | 一本精品99久久精品77| 网址你懂的国产日韩在线| 午夜a级毛片| 成人午夜高清在线视频| 高清毛片免费看| 欧美不卡视频在线免费观看| 精品人妻视频免费看| 国产精品爽爽va在线观看网站| 国产麻豆成人av免费视频| 亚洲人成网站高清观看| 99久久九九国产精品国产免费| 久久热精品热| 亚洲熟妇中文字幕五十中出| 日本a在线网址| 天堂影院成人在线观看| 一卡2卡三卡四卡精品乱码亚洲| 成人美女网站在线观看视频| 亚洲最大成人中文| 日本免费一区二区三区高清不卡| 波多野结衣高清作品| 人妻少妇偷人精品九色| 欧美高清成人免费视频www| 一区福利在线观看| 性插视频无遮挡在线免费观看| 最近2019中文字幕mv第一页| 黄色欧美视频在线观看| 久久精品人妻少妇| 狂野欧美激情性xxxx在线观看| 午夜福利成人在线免费观看| 日韩精品中文字幕看吧| 看非洲黑人一级黄片| 老司机影院成人| 黄色欧美视频在线观看| 人妻夜夜爽99麻豆av| 国产黄a三级三级三级人| 1024手机看黄色片| 国产精品不卡视频一区二区| 亚洲av.av天堂| 美女 人体艺术 gogo| 看十八女毛片水多多多| 亚洲精品色激情综合| 国产视频内射| 三级男女做爰猛烈吃奶摸视频| 亚洲内射少妇av| 蜜桃亚洲精品一区二区三区| 亚洲av二区三区四区| 久久久久久久久久黄片| 亚洲国产色片| 91狼人影院| 3wmmmm亚洲av在线观看| 日本爱情动作片www.在线观看 | 婷婷精品国产亚洲av| 91av网一区二区| 观看美女的网站| 中出人妻视频一区二区| 亚洲最大成人中文| 最新中文字幕久久久久| 久久天躁狠狠躁夜夜2o2o| 欧洲精品卡2卡3卡4卡5卡区| 国产黄片美女视频| 久久亚洲精品不卡| 99久久无色码亚洲精品果冻| 亚洲久久久久久中文字幕| 大香蕉久久网| 久久久久久伊人网av| 国产一区二区亚洲精品在线观看| 禁无遮挡网站| 午夜久久久久精精品| 一级黄色大片毛片| 精品一区二区免费观看| 久久久久国内视频| 老师上课跳d突然被开到最大视频| 成人亚洲欧美一区二区av| 久久精品综合一区二区三区| 午夜激情欧美在线| 日日摸夜夜添夜夜添av毛片| 亚洲精品亚洲一区二区| 久久精品综合一区二区三区| 乱系列少妇在线播放| 看片在线看免费视频| 男女啪啪激烈高潮av片| 欧美性猛交黑人性爽| 亚洲不卡免费看| 久久热精品热| 免费人成视频x8x8入口观看| 国产aⅴ精品一区二区三区波| 亚洲第一区二区三区不卡| 国产av不卡久久| 亚洲av不卡在线观看| 亚洲电影在线观看av| 色哟哟·www| 日韩欧美国产在线观看| 成人av一区二区三区在线看| 国产成人a∨麻豆精品| 成人美女网站在线观看视频| 蜜臀久久99精品久久宅男| 久久天躁狠狠躁夜夜2o2o| 成人av在线播放网站| 网址你懂的国产日韩在线| 日韩三级伦理在线观看| 99热这里只有是精品在线观看| 亚洲精品一卡2卡三卡4卡5卡| 噜噜噜噜噜久久久久久91| 久久精品国产亚洲av天美| 一区二区三区高清视频在线| 一个人观看的视频www高清免费观看| 可以在线观看毛片的网站| 一级a爱片免费观看的视频| 亚洲欧美清纯卡通| 97超碰精品成人国产| 97人妻精品一区二区三区麻豆| 一本久久中文字幕| 91狼人影院| 99久久精品热视频| 精品一区二区三区视频在线| 搞女人的毛片| a级毛片a级免费在线| 亚洲欧美日韩高清在线视频| 亚洲成人中文字幕在线播放| 非洲黑人性xxxx精品又粗又长| 成人高潮视频无遮挡免费网站| 黑人高潮一二区| 久久精品夜色国产| 黄色一级大片看看| 床上黄色一级片| 中文字幕免费在线视频6| 22中文网久久字幕| 免费观看人在逋| 色尼玛亚洲综合影院| 日本免费一区二区三区高清不卡| 日本a在线网址| 中文字幕久久专区| av国产免费在线观看| 国产亚洲av嫩草精品影院| 欧美激情国产日韩精品一区| 亚洲av.av天堂| 久久草成人影院| 人人妻人人澡欧美一区二区| 18禁裸乳无遮挡免费网站照片| 亚洲,欧美,日韩| 久久久精品94久久精品| 色av中文字幕| 身体一侧抽搐| 免费大片18禁| 啦啦啦观看免费观看视频高清| 美女免费视频网站| 毛片女人毛片| 特级一级黄色大片| 国产亚洲91精品色在线| 精品久久久久久成人av| 男人舔奶头视频| 少妇猛男粗大的猛烈进出视频 | 久久婷婷人人爽人人干人人爱| 亚洲最大成人手机在线| 国产精品野战在线观看| 搡老岳熟女国产| 亚洲欧美中文字幕日韩二区| h日本视频在线播放| 丰满乱子伦码专区| 国产91av在线免费观看| 欧美一区二区精品小视频在线| 精品久久久久久久末码| 老熟妇乱子伦视频在线观看| 成人漫画全彩无遮挡| 蜜桃亚洲精品一区二区三区| 美女cb高潮喷水在线观看| 免费av不卡在线播放| a级毛片免费高清观看在线播放| 欧美国产日韩亚洲一区| 午夜福利在线在线| 在线免费十八禁| 国产午夜福利久久久久久| 欧美xxxx黑人xx丫x性爽| 国产伦精品一区二区三区四那| 日本与韩国留学比较| 国产精品伦人一区二区| 成人精品一区二区免费| 五月伊人婷婷丁香| 一级毛片我不卡| 在线国产一区二区在线| 久久精品国产亚洲av香蕉五月| 亚洲四区av| 国产伦一二天堂av在线观看| 国产精品久久久久久精品电影| 别揉我奶头~嗯~啊~动态视频| 亚洲,欧美,日韩| 日日撸夜夜添| 极品教师在线视频| 97碰自拍视频| 性色avwww在线观看| 老熟妇乱子伦视频在线观看| 亚洲熟妇熟女久久| 精品久久久久久久久久久久久| 午夜影院日韩av| 欧美色视频一区免费| 女同久久另类99精品国产91| 乱人视频在线观看| 久久久精品大字幕| 久久这里只有精品中国| 日韩 亚洲 欧美在线| 亚洲经典国产精华液单| 久久久精品欧美日韩精品| 国产aⅴ精品一区二区三区波| 亚洲美女黄片视频| 老司机影院成人| 婷婷亚洲欧美| 精品久久久久久久久av| 亚洲成av人片在线播放无| 赤兔流量卡办理| 色综合亚洲欧美另类图片| 国产亚洲欧美98| 成人av一区二区三区在线看| 日韩欧美免费精品| 午夜免费男女啪啪视频观看 | 成人午夜高清在线视频| 国产在线男女| 国产精品一及| 成年av动漫网址| 国产男靠女视频免费网站| 一本久久中文字幕| 成人永久免费在线观看视频| 亚洲av成人av| 成年av动漫网址| 91午夜精品亚洲一区二区三区| 中国美女看黄片| 一本精品99久久精品77| 三级国产精品欧美在线观看| 亚洲av一区综合| 亚洲av成人精品一区久久| 国产精品福利在线免费观看| 男人的好看免费观看在线视频| 91在线观看av| 亚洲av美国av| 久久精品国产99精品国产亚洲性色| 日本-黄色视频高清免费观看| 欧美一区二区亚洲| 国产在线精品亚洲第一网站| 国产真实伦视频高清在线观看| 日本一二三区视频观看| 老熟妇乱子伦视频在线观看| 狂野欧美激情性xxxx在线观看| 99热这里只有是精品50| 久久久成人免费电影| 精品午夜福利视频在线观看一区| 久久热精品热| 日韩高清综合在线| 看免费成人av毛片| 成人特级av手机在线观看| 老女人水多毛片| avwww免费| 色视频www国产| 天天躁夜夜躁狠狠久久av| 久久九九热精品免费| 三级男女做爰猛烈吃奶摸视频| 亚洲av熟女| 欧美日本视频| 男女边吃奶边做爰视频| 久久久精品大字幕| 国产精品av视频在线免费观看| 久久精品国产亚洲网站| 日本黄大片高清| 久久午夜福利片| 久久久久国产精品人妻aⅴ院| 日韩强制内射视频| 亚洲在线观看片| 国产精品,欧美在线| 精品久久久久久成人av| 少妇被粗大猛烈的视频| 天天躁日日操中文字幕| 亚洲av成人精品一区久久| 久久这里只有精品中国| 中出人妻视频一区二区| 日韩人妻高清精品专区| 国产片特级美女逼逼视频| 亚洲欧美精品自产自拍| 一级毛片我不卡| 黄色日韩在线| 亚洲av熟女| 熟妇人妻久久中文字幕3abv| 成人特级av手机在线观看| 国产在线男女| 有码 亚洲区| 老女人水多毛片| 久久精品国产自在天天线| 韩国av在线不卡| 人妻夜夜爽99麻豆av| 97热精品久久久久久| 欧美激情久久久久久爽电影| 国产一区二区三区在线臀色熟女| 又黄又爽又刺激的免费视频.| 一区福利在线观看| 美女高潮的动态| 亚洲精品日韩在线中文字幕 | 丰满人妻一区二区三区视频av| 99久久成人亚洲精品观看| 国产一区二区在线观看日韩| 国产v大片淫在线免费观看| 少妇丰满av| 国产91av在线免费观看| 日本 av在线| 欧洲精品卡2卡3卡4卡5卡区| 国产高清激情床上av| 欧美国产日韩亚洲一区| 丰满的人妻完整版| 成人综合一区亚洲| a级毛片免费高清观看在线播放| 欧美日本视频| 日本免费a在线| 伊人久久精品亚洲午夜| 两个人视频免费观看高清| 黄色配什么色好看| 亚洲国产精品成人综合色| 国产精品1区2区在线观看.| 久久久久国内视频| 夜夜看夜夜爽夜夜摸| 亚洲四区av| 国内少妇人妻偷人精品xxx网站| 热99re8久久精品国产| 日产精品乱码卡一卡2卡三| 成人二区视频| 一区福利在线观看| av黄色大香蕉| 长腿黑丝高跟| 在线国产一区二区在线| 日韩欧美免费精品|